Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread? (TRANSBioHIV)
Primary Purpose
HIV Infection
Status
Completed
Phase
Not Applicable
Locations
France
Study Type
Interventional
Intervention
Blood sample
Sponsored by
About this trial
This is an interventional basic science trial for HIV Infection focused on measuring HIV, Biofilm, Transmission
Eligibility Criteria
Inclusion Criteria:
- Age ≥ 18 years
- able to give written consent
- HIV positive serology HIV1
- Viral load > 10 000 copies/ml
- CD4 T cells > 100 cells/mm3
- or Treated by antiretroviral therapy (ARV) for less than 6 months
- Covered by French Social Security
Exclusion Criteria:
- Involved in a clinical trial
- Pregnancy (inclusion can be postponed)
- No covered by French Social Security
Sites / Locations
- Service de Médecine Interne, CHU Kremlin-Bicêtre
Arms of the Study
Arm 1
Arm Type
Experimental
Arm Label
HIV infection
Arm Description
20 HIV infected subjects
Outcomes
Primary Outcome Measures
The percentage of HIV positive patients with cells producing biofilms.
Secondary Outcome Measures
The number of cells with biofilms identified among the HIV positive patients presenting such structures.
Full Information
NCT ID
NCT01895920
First Posted
July 2, 2013
Last Updated
February 26, 2018
Sponsor
ANRS, Emerging Infectious Diseases
1. Study Identification
Unique Protocol Identification Number
NCT01895920
Brief Title
Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?
Acronym
TRANSBioHIV
Study Type
Interventional
2. Study Status
Record Verification Date
May 2017
Overall Recruitment Status
Completed
Study Start Date
January 2013 (Actual)
Primary Completion Date
February 2018 (Actual)
Study Completion Date
February 2018 (Actual)
3. Sponsor/Collaborators
Responsible Party, by Official Title
Sponsor
Name of the Sponsor
ANRS, Emerging Infectious Diseases
4. Oversight
Data Monitoring Committee
No
5. Study Description
Brief Summary
This project aims at characterizing HIV-1 viral biofilms structural and functional properties and at deciphering its role as a new viral reservoir and as a new mode of viral spread. The prospective national study will be conducted on cells isolated from blood samples from 20 patients infected with HIV.
Detailed Description
The investigators' preliminary data indicate that besides " free " infectious viral particles, HIV-1 infected cluster of differentiation 4 (CD4+) lymphocytes also produce extracellular viral assemblies wrapped in an extracellular matrix cocoon and tightly bound to the surface of the cell. Importantly, these structures are infectious, transferred to target cells upon intercellular contacts and they are key role in HIV-1 spread between T lymphocytes. HIV-1 viral biofilm could be important not only for direct transmission of the virions but also for " trans-infection ", a process our objectives are:
to better characterize the molecular composition and the architecture of this biofilm (using proteomics, glycomic superresolution cell imaging approaches) with regard to its properties (infectivity, adhesiveness, protection of virions) and to determine whether cells from infected patients produce such structures.
to delineate the viral factors regulating the formation of these new infectious structures (with a particular attention on Tat, Vpu and Nef HIV-1 encoded using mutant viruses or expression vectors).
to investigate the lymphocyte pathways regulating the viral biofilms formation and composition in extracellular matrix (ECM) proteins (using quantitative polymerase chain reaction (qPCR) and siRNA).
to determine whether those viral biofilms are involved in HIV-1 transmission by transinfection
to study the contribution of those infectious structures and the dynamics of their transmission in lymph nodes.
This project may contribute to decipher the role of viral biofilms in HIV-1 transmission. Ultimately, we intend to determine how the interference of retroviral infections with T cell activation pathways modulates the pattern of ECM production by T cells, tuning viral biofilm composition and regulating viral dissemination.
6. Conditions and Keywords
Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
HIV Infection
Keywords
HIV, Biofilm, Transmission
7. Study Design
Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
8. Arms, Groups, and Interventions
Arm Title
HIV infection
Arm Type
Experimental
Arm Description
20 HIV infected subjects
Intervention Type
Other
Intervention Name(s)
Blood sample
Primary Outcome Measure Information:
Title
The percentage of HIV positive patients with cells producing biofilms.
Time Frame
2 years
Secondary Outcome Measure Information:
Title
The number of cells with biofilms identified among the HIV positive patients presenting such structures.
Time Frame
2 years
10. Eligibility
Sex
All
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
70 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria:
Age ≥ 18 years
able to give written consent
HIV positive serology HIV1
Viral load > 10 000 copies/ml
CD4 T cells > 100 cells/mm3
or Treated by antiretroviral therapy (ARV) for less than 6 months
Covered by French Social Security
Exclusion Criteria:
Involved in a clinical trial
Pregnancy (inclusion can be postponed)
No covered by French Social Security
Facility Information:
Facility Name
Service de Médecine Interne, CHU Kremlin-Bicêtre
City
Le Kremlin Bicêtre
ZIP/Postal Code
94270
Country
France
12. IPD Sharing Statement
Learn more about this trial
Viral Biofilms: Hijacking T Cell Extracellular Matrix to Regulate HIV-1 Spread?
We'll reach out to this number within 24 hrs